We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The company posted adjusted earnings per share (EPS) of $2.13 in the last reported quarter, which topped the Zacks Consensus Estimate by 7.6%. Align Technology beat on earnings in each of the trailing four quarters, the average surprise being 3.40%.
ALGN’s Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.06 billion, which suggests a rise of 3.2% from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.57 per share, which implies a 6.6% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q2 Earnings
Estimates for second-quarter earnings have remained unchanged at $2.57 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Factors at Play
Clear Aligner Business
Similar to the last reported quarter, Align Technology is likely to have witnessed strength in Clear Aligner volumes for teens and adult patient, reflecting growth across regions, especially APAC and EMEA. Growth in the APAC and EMEA regions is likely to have been driven the orthodontic and GP dentist channels across teens, kids and adult patients. Meanwhile, we expect Clear Aligner volume growth in in North America to have persisted in the to-be-reported quarter, driven by growth in Invisalign DSP touch-up cases, Invisalign Palate Expander system, as well as Invisalign Comprehensive Three and Three.
In the first quarter, Clear Aligner volume from DSO customers increased year over year, reflecting growth across all regions. The DSO business in the United States continued to outpace the retail doctors, driven by the company’s largest DSO partners — SmileDoctors and Heartland Dental. This might have benefited the company’s quarterly top line.
In the second quarter, its Invisalign Palatal Expander System received approval from the National Medical Products Administration (“NMPA”) in China. Additionally, Align Technology introduced the Invisalign System with mandibular advancement featuring occlusal blocks. It is designed to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. The system is commercially available in the United States, Canada, Australia and New Zealand. These factors, too, might have aided Align Technology’s second-quarter revenues.
The Systems & Services business is projected to have witnessed growth in the second quarter due to increased scanner volumes and non-system revenues driven by iTero Lumina wand upgrades. The continuous uptake of the iTero Lumina Scanner with ortho workflow and positive response from customers are likely to have boosted the company’s revenues.
In the previous quarter, Align Technology launched its next-generation iTero Lumina solutions with comprehensive capabilities, including the Near Infra-Red Imaging technology in the iTero Lumina Pro dental imaging system. Also, it launched Align X-ray Insights — a new software-based computer-aided detection solution that uses artificial intelligence (AI) to automatically analyze 2D radiographs — in the EU countries and the United Kingdom. We expect these developments to have positively impacted the company’s second-quarter top line.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, that is not the case here, as you can see below:
Earnings ESP: Align Technologies has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle:
CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?
Key Takeaways
Align Technology, Inc. (ALGN - Free Report) is set to release second-quarter 2025 results on July 30, after the closing bell.
The company posted adjusted earnings per share (EPS) of $2.13 in the last reported quarter, which topped the Zacks Consensus Estimate by 7.6%. Align Technology beat on earnings in each of the trailing four quarters, the average surprise being 3.40%.
ALGN’s Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.06 billion, which suggests a rise of 3.2% from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at $2.57 per share, which implies a 6.6% rise from the year-ago recorded actuals.
Estimate Revision Trend Ahead of ALGN’s Q2 Earnings
Estimates for second-quarter earnings have remained unchanged at $2.57 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Factors at Play
Clear Aligner Business
Similar to the last reported quarter, Align Technology is likely to have witnessed strength in Clear Aligner volumes for teens and adult patient, reflecting growth across regions, especially APAC and EMEA. Growth in the APAC and EMEA regions is likely to have been driven the orthodontic and GP dentist channels across teens, kids and adult patients. Meanwhile, we expect Clear Aligner volume growth in in North America to have persisted in the to-be-reported quarter, driven by growth in Invisalign DSP touch-up cases, Invisalign Palate Expander system, as well as Invisalign Comprehensive Three and Three.
In the first quarter, Clear Aligner volume from DSO customers increased year over year, reflecting growth across all regions. The DSO business in the United States continued to outpace the retail doctors, driven by the company’s largest DSO partners — SmileDoctors and Heartland Dental. This might have benefited the company’s quarterly top line.
In the second quarter, its Invisalign Palatal Expander System received approval from the National Medical Products Administration (“NMPA”) in China. Additionally, Align Technology introduced the Invisalign System with mandibular advancement featuring occlusal blocks. It is designed to address Class II skeletal and dental correction by simultaneously advancing the mandible while aligning the teeth. The system is commercially available in the United States, Canada, Australia and New Zealand. These factors, too, might have aided Align Technology’s second-quarter revenues.
Align Technology, Inc. Price and EPS Surprise
Align Technology, Inc. price-eps-surprise | Align Technology, Inc. Quote
Imaging Systems & CAD/CAM Service Business
The Systems & Services business is projected to have witnessed growth in the second quarter due to increased scanner volumes and non-system revenues driven by iTero Lumina wand upgrades. The continuous uptake of the iTero Lumina Scanner with ortho workflow and positive response from customers are likely to have boosted the company’s revenues.
In the previous quarter, Align Technology launched its next-generation iTero Lumina solutions with comprehensive capabilities, including the Near Infra-Red Imaging technology in the iTero Lumina Pro dental imaging system. Also, it launched Align X-ray Insights — a new software-based computer-aided detection solution that uses artificial intelligence (AI) to automatically analyze 2D radiographs — in the EU countries and the United Kingdom. We expect these developments to have positively impacted the company’s second-quarter top line.
What Our Quantitative Model Predicts for ALGN
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates. However, that is not the case here, as you can see below:
Earnings ESP: Align Technologies has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle:
CVS Health (CVS - Free Report) has an Earnings ESP of +2.06% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2025 results on July 31. You can see the complete list of today’s Zacks #1 Rank stocks here.
CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.08%. The Zacks Consensus Estimate for second-quarter EPS implies a year-over-year decline of 19.7%.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.